DISCONTINUED OPERATIONS

9 Months Ended

Sep. 30, 2017

Discontinued Operations and Disposal Groups [Abstract]

DISCONTINUED OPERATIONS

NOTE 4 – DISCONTINUED OPERATIONS

The Company accounted for the termination of the Pfizer Agreement and the sale of the license as a discontinued operation, in accordance with ASU No. 2014-08. The following assets and liabilities associated with the Company’s discontinued operations have been segregated and classified as assets and liabilities of discontinued operations, as appropriate, in the consolidated balance sheets as of September 30, 2017 and December 31, 2016, respectively:

	September 30, 2017		December 31, 2016
	(U.S. dollars in thousands)
CURRENT ASSETS:
Accounts receivable - Trade	$	211	$	327
Total current assets of discontinued operations	$	211	$	327

The following summarizes financial information related to the Company’s discontinued operations in the Company’s consolidated statements of operations for the nine months ended September 30, 2017 and September 30, 2016:

	Nine months ended September 30,
	2017		2016
	(U.S. dollars in thousands)
REVENUES			$	209
COST OF REVENUES				(373)
GROSS LOSS				(164)
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES				(25)
NET LOSS FOR THE PERIOD FROM DISCONTINUED OPERATIONS		-	$	(189)